PBYI's Volatility: Speculative Stock with Nerlynx
Update: 2025-12-31
Description
Puma Biotechnologys stock, PBYI, has surged 91% in a year, reaching a 52-week high of $6.27. The companys sole drug, Nerlynx, is approved for early-stage HER2-positive breast cancer in the US and Europe. Despite technical buy signals and international licensing deals, analysts rate it a hold or sell, with low price targets. The stocks volatile and speculative, driven by momentum, not solid growth. Revenue is expected to dip 4% this year, and earnings keep sliding. Proceed with caution. Checkout Solipillow.com
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
